Kadcyla (trastuzumab emtansine): Reviews and patient testimonials


/static/themes-v3/default/images/default/opinion/traitement/intro.jpg?1564492295

Back Back to the list of medications

Medication indications

Kadcyla 100 mg & 160 mg Powder for Concentrate for Solution for Infusion

Kadcyla, as a single agent, is indicated for the treatment of adult patients with HER2-positive,

unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:

• Received prior therapy for locally advanced or metastatic disease, or

• Developed disease recurrence during or within six months of completing adjuvant therapy.


Route of administration: Injectable
Molecule: trastuzumab emtansine

Patients' opinions on Kadcyla

In brief

General satisfaction level: Be the first to evaluate

Treatment's effectiveness: Be the first to evaluate

Ease of use: Be the first to evaluate

Adherence to prescription: Be the first to evaluate

Detected side effects: Be the first to evaluate

Improvement in the quality of life: Be the first to evaluate

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community

Join Carenity and be the first to give your opinion on this medication.

Conditions related to this medication

Fact sheet

Breast cancer

See the fact sheet